- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01688349
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome (LIPOCUSH)
Comparative Study of Subcutaneous and Visceral Adipose Tissue in Patients Affected by Cushing Syndrome Versus 2 Controls Population
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be
- to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;
- to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Cushing's syndrome is a rare disease resulting from chronic exposure to glucocorticoids (endogenous or iatrogenic) with abnormal fat distribution (lipodystrophy). Glucocorticoids regulate the functions of adipose tissue (AT) targeting adipocyte differentiation as well as anabolic, catabolic and secretory pathways of the adipocyte. However, the mechanisms by which glucocorticoids differentially disrupt the development or metabolism of AT between deep and superficial deposits remain unknown. Among the main effectors of the glucocorticoid signaling pathway, 11 beta-hydroxysteroid deshydrogenase (11beta-HSD1) , that regenerate cortisol from cortisone, is likely a key step in the biological effect of glucocorticoids in AT. Identifying these mechanisms of action of glucocorticoids on different fat depots requires the comparison with fatty deposits derived from two types of control populations: 1/ normal weight individuals without inflammatory or metabolic disorder (controls1); 2/individuals obese matched for the level of insulin resistance (controls2).
Hypothesis: Excess glucocorticoids cause abnormal fat distribution via a direct effect on the various deposits of AT, leading secondarily to insulin resistance.
Primary endpoint: To compare gene expression of glucocorticoid signaling between the visceral AT (VAT) of Cushing patients with that of controls1 (matched for age and sex).
Secondary endpoints:
For patients with Cushing and controls1, to compare their respective subcutaneous AT (SCAT) and VAT for:
- The expression of genes involved in differentiation and inflammation of the AT,
- Morphological aspects: adipocyte size, fibrosis, inflammation, immunohistochemistry.
- Same parameters for Cushing patients and controls2 (matched for sex, age + / -5, HOMA-R + / -1), to differentiate the specific effects of glucocorticoid from the effects of insulin resistance,
- To compare these parameters between SCAT and VAT from Cushing patients. Methodology and experimental design: non-randomized comparative multicenter study with constitution of a biological collection.
Patients will be recruited in endocrinology before adrenalectomy and controls1 in urology. They will have a preoperative assessment and sampling of perirenal AT and SCAT at surgery. Controls2 are already included in the CRC2007-P050318 and will be drawn for matching.
Number of patients needed: We assume the relative gene expression of 11β-HSD1 in the VAT not exposed to glucocorticoids = 0.81 ± 0.121. Our recruitment potential of Cushing patients is 30 patients. With 30 patients per group, we will be able to detect a difference in 11β-HSD1 gene expression in the VAT of Cushing patients at least 15% higher compared to controls1.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Paris, Franciaország, 75012
- Hôpital Saint-Antoine, service d'Endocrinologie
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Cases: Adults with Cushing's syndrome secondary to adrenal adenoma.
- Controls1: Adults with normal weight: BMI <25, having partial nephrectomy
- Controls2 adults with common obesity treated by bariatric surgery, BMI> 35kg/m2
Exclusion Criteria:
- Diabetes, renal or hepatic impairment, pregnancy, menopause, HIV or HCV, Cushing's syndrome due to other causes than cortisol adenoma
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Alapvető tudomány
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Cushing group
AT biopsy during partial nephrectomy
|
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be
|
Egyéb: Controls1
normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
|
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be
|
Egyéb: Controls2
obese individuals already included and having biopsies of VAT and SCAT stocked.
|
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Comparison between visceral adipose tissue of Cushing patients and that of normal weight controls.
Időkeret: 1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
Comparison of glucocorticoid pathway genes expression between visceral adipose tissue of Cushing patients and that of normal weight controls matched on sex and age.
|
1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Comparison of the respective SCAT and VAT between Cushing patients and normal weight controls.
Időkeret: 1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
For patients with Cushing and controls1, to compare their respective SCAT and VAT for:
|
1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
Comparison of the respective SCAT and VAT between Cushing patients and obese controls.
Időkeret: 1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
Comparison of these same parameters(secondary outcome n°1) between Cushing patients and controls2 (matched for sex, age + / -5, HOMA-R + / -1), to differentiate the specific effects of glucocorticoid from the effects of insulin resistance
|
1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
comparison between SCAT and VAT from Cushing patients
Időkeret: 1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
To compare these parameters between SCAT and VAT from Cushing patients
|
1 day (gene expression will be tested on AT withdraw the day of surgical adrenalectomy)
|
Együttműködők és nyomozók
Nyomozók
- Kutatásvezető: Bruno Feve, PhD, Assistance Publique
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Patológiás folyamatok
- Neoplazmák szövettani típus szerint
- Neoplazmák
- Neoplazmák, mirigyes és epiteliális
- Endokrin rendszer betegségei
- Betegség
- Mellékvesekéreg hiperfunkció
- Mellékvese betegségei
- Szindróma
- Adenoma
- Cushing szindróma
- A gyógyszerek élettani hatásai
- Hormonok
- Hormonok, hormonpótlók és hormonantagonisták
- Glükokortikoidok
Egyéb vizsgálati azonosító számok
- P110906
- CRC11001 (Egyéb azonosító: Assistance Publique)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .